PCYOX1

Across TCGA pan-cancer cohorts, PCYOX1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCYOX1 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCYOX1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCYOX1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where PCYOX1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.809	0.998	<.001	41	view →
UCEC	OS	Median	III,IV	0.433	1.000	.007	20	view →
CCRCC	DFS	Quartile	All	1.000	0.788	.002	13	view →
PDAC	DFS	Median	All	0.265	0.435	.018	10	view →
HNSC	DFS	Quartile	III,IV	0.939	0.711	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCYOX1–LUAD (DFS)

Open the LUAD breakdown →